Literature DB >> 7657439

Malignant syphilis (lues maligna) and concurrent infection with HIV.

P C Don1, R Rubinstein, S Christie.   

Abstract

BACKGROUND: During the past 2 1/2 years we observed six patients who had a reactive serology for syphilis, of which four developed widespread noduloulcerative and two vesiculonecrotic lesions. The purpose was to report the occurrence of lues maligna, a rare form of secondary syphilis, in five patients infected with the human immunodeficiency virus (HIV) and in one patient with risk factors for infection.
METHODS: Tzanck preparations, viral cultures, and skin biopsies were performed to evaluate the etiology of the lesions.
RESULTS: Syphilis serology titers ranged from 1:32 to 1:128 and in one instance was as low as 1:8. Such titers can also be found in patients with the latent form of syphilis. Therefore, confirmation of the clinical diagnosis of lues maligna was dependent on skin biopsies that were compatible with secondary syphilis and negative viral studies that excluded varicella, disseminated varicella-zoster or herpes simplex. Lues maligna takes an aggressive course in HIV-infected patients since four of the patients required hospitalization and the two patients who refused to complete treatment, subsequently developed more severe skin and constitutional symptoms.
CONCLUSIONS: HIV-infected patients are at risk for developing lues maligna. Despite its malignant presentation, lues maligna lesions respond rapidly to treatment with penicillin. Secondary syphilis should be added to the list of diseases known to be more aggressive in HIV-infected patients.

Entities:  

Mesh:

Year:  1995        PMID: 7657439     DOI: 10.1111/j.1365-4362.1995.tb04441.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  9 in total

1.  [HIV-positive patient with multiple ulcers. Lues maligna].

Authors:  A Körber; J Dissemond; U Hillen; M Goos; St Esser
Journal:  Hautarzt       Date:  2003-11       Impact factor: 0.751

Review 2.  Secondary syphilitic lesions.

Authors:  Robert E Baughn; Daniel M Musher
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 3.  Biological basis for syphilis.

Authors:  Rebecca E Lafond; Sheila A Lukehart
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Malignant syphilis in an AIDS patient.

Authors:  T R dos Santos; I J de Castro; M M B Dahia; M C V M de Azevedo; G A R da Silva; R N Motta; J da Cunha Pinto; F R de Almeida Ferry
Journal:  Infection       Date:  2014-11-19       Impact factor: 3.553

5.  Host defense mechanisms in secondary syphilitic lesions: a role for IFN-gamma-/IL-17-producing CD8+ T cells?

Authors:  Georg Stary; Irene Klein; Marie-Charlotte Brüggen; Sabine Kohlhofer; Patrick M Brunner; Daniel Spazierer; Leonhard Müllauer; Peter Petzelbauer; Georg Stingl
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

Review 6.  The immunopathobiology of syphilis: the manifestations and course of syphilis are determined by the level of delayed-type hypersensitivity.

Authors:  J Andrew Carlson; Ganary Dabiri; Bernard Cribier; Stewart Sell
Journal:  Am J Dermatopathol       Date:  2011-07       Impact factor: 1.533

7.  Malignant syphilis with human immunodeficiency virus infection.

Authors:  Jiby Rajan; P V S Prasad; K Chockalingam; P K Kaviarasan
Journal:  Indian Dermatol Online J       Date:  2011-01

8.  A case of rupioid syphilis masquerading as aggressive cutaneous lymphoma.

Authors:  Jonathan Braue; Thomas Hagele; Abraham Tareq Yacoub; Suganya Mannivanan; Lubomir Sokol; Frank Glass; John N Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-04-20       Impact factor: 2.576

9.  Human immunodeficiency virus-positive secondary syphilis mimicking cutaneous T-cell lymphoma.

Authors:  Michiko Yamashita; Yoshiyuki Fujii; Keiji Ozaki; Yoshio Urano; Masami Iwasa; Shingen Nakamura; Shiro Fujii; Masahiro Abe; Yasuharu Sato; Tadashi Yoshino
Journal:  Diagn Pathol       Date:  2015-10-08       Impact factor: 2.644

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.